REG - Haleon PLC - Notice of Annual General Meeting (AGM)

HALEONAnnouncement

12/04/2024 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240412:nRSL4729Ka&default-theme=true

RNS Number : 4729K  Haleon PLC  12 April 2024

 

 

Haleon plc: Notice of Annual General Meeting (AGM)

 

12 April 2024: Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that
the following documents have been made available to shareholders:

 

1.  Notice of 2024 Annual General Meeting (the "Notice")

2.  Form of Proxy for 2024 Annual General Meeting

3.  AGM Voting Instruction Card

 

The Company's AGM will be a virtual meeting, broadcast under studio conditions
from the Company's London offices at 3.00pm (BST) on Wednesday 8 May 2024. The
Notice is available on the Company's website at
http://www.haleon.com/investors/shareholder-information/annual-general-meetings
(http://www.haleon.com/investors/shareholder-information/annual-general-meetings)
, and includes full details of the business to be conducted and joining
instructions.

In compliance with Listing Rule 9.6.1, a copy of the above documents has been
submitted to the National Storage Mechanism and will shortly be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

 

Amanda Mellor, Company Secretary

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAGPUPACUPCGUP